These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 25700624)
1. Impact of clinical characteristics and management on the prognosis of unselected heart failure patients. Eschalier R; Chenaf C; Mulliez A; Yalioua A; Clerfond G; Authier N; Vorilhon C; Citron B; Pereira B; Jean F; Souteyrand G; Motreff P; Eschalier A; Lusson JR Cardiovasc Drugs Ther; 2015 Feb; 29(1):89-98. PubMed ID: 25700624 [TBL] [Abstract][Full Text] [Related]
2. Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort. Vorilhon C; Chenaf C; Mulliez A; Pereira B; Clerfond G; Authier N; Jean F; Motreff P; Citron B; Eschalier A; Lusson JR; Eschalier R Eur J Clin Pharmacol; 2015 Feb; 71(2):251-60. PubMed ID: 25537794 [TBL] [Abstract][Full Text] [Related]
3. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases. Kruik-Kollöffel WJ; van der Palen J; Doggen CJM; van Maaren MC; Kruik HJ; Heintjes EM; Movig KLL; Linssen GCM PLoS One; 2020; 15(12):e0244231. PubMed ID: 33351823 [TBL] [Abstract][Full Text] [Related]
4. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey. Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M; Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720 [TBL] [Abstract][Full Text] [Related]
5. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure. Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928 [TBL] [Abstract][Full Text] [Related]
6. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling. Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879 [TBL] [Abstract][Full Text] [Related]
7. Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study. Bitar S; Thilly N; Agrinier N Eur J Clin Pharmacol; 2021 Oct; 77(10):1569-1581. PubMed ID: 33970296 [TBL] [Abstract][Full Text] [Related]
8. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Traditional Heart Failure Therapies in Patients With Cardiac Amyloidosis and Heart Failure. Yan CL; Gallo RA; Vasquez Martinez M; Rivera Rodriguez B; Trujillo L; Thakkar Rivera N; Hoffman JE Am J Cardiol; 2023 Oct; 204():360-365. PubMed ID: 37573615 [TBL] [Abstract][Full Text] [Related]
10. Prescribing and up-titration in recently hospitalized heart failure patients attending a disease management program. Carroll R; Mudge A; Suna J; Denaro C; Atherton J Int J Cardiol; 2016 Aug; 216():121-7. PubMed ID: 27153136 [TBL] [Abstract][Full Text] [Related]
11. Heart failure medications prescribed at discharge for patients with left ventricular assist devices. Shreibati JB; Sheng S; Fonarow GC; DeVore AD; Yancy CW; Bhatt DL; Schulte P; Peterson ED; Hernandez A; Heidenreich PA Am Heart J; 2016 Sep; 179():99-106. PubMed ID: 27595684 [TBL] [Abstract][Full Text] [Related]
12. Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015. Kruik-Kollöffel WJ; Linssen GCM; Kruik HJ; Movig KLL; Heintjes EM; van der Palen J Heart Fail Rev; 2019 Jul; 24(4):499-510. PubMed ID: 30848404 [TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Kimmoun A; Cotter G; Davison B; Takagi K; Addad F; Celutkiene J; Chioncel O; Solal AC; Diaz R; Damasceno A; Duengen HD; Filippatos G; Goncalvesova E; Merai I; Metra M; Ponikowski P; Privalov D; Sliwa K; Sani MU; Voors AA; Shogenov Z; Mebazaa A Eur J Heart Fail; 2019 Nov; 21(11):1459-1467. PubMed ID: 31423712 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333 [TBL] [Abstract][Full Text] [Related]
15. Adherence and persistence to pharmacotherapy in patients with heart failure: a nationwide cohort study, 2014-2020. Ødegaard KM; Lirhus SS; Melberg HO; Hallén J; Halvorsen S ESC Heart Fail; 2023 Feb; 10(1):405-415. PubMed ID: 36266969 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological treatment patterns in heart failure: a population-based cohort study. Bosco-Lévy P; Favary C; Jové J; Lassalle R; Moore N; Droz-Perroteau C Eur J Clin Pharmacol; 2020 Jan; 76(1):97-106. PubMed ID: 31637454 [TBL] [Abstract][Full Text] [Related]
17. If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment? Dierckx R; Cleland JG; Pellicori P; Zhang J; Goode K; Putzu P; Boyalla V; Clark AL J Telemed Telecare; 2015 Sep; 21(6):331-9. PubMed ID: 25766855 [TBL] [Abstract][Full Text] [Related]
18. Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. Savarese G; Edner M; Dahlström U; Perrone-Filardi P; Hage C; Cosentino F; Lund LH Int J Cardiol; 2015 Nov; 199():415-23. PubMed ID: 26247798 [TBL] [Abstract][Full Text] [Related]
19. First hospitalization for heart failure in France in 2009: patient characteristics and 30-day follow-up. Tuppin P; Cuerq A; de Peretti C; Fagot-Campagna A; Danchin N; Juillière Y; Alla F; Allemand H; Bauters C; Drici MD; Hagège A; Jondeau G; Jourdain P; Leizorovicz A; Paccaud F Arch Cardiovasc Dis; 2013 Nov; 106(11):570-85. PubMed ID: 24140417 [TBL] [Abstract][Full Text] [Related]
20. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. Banka G; Heidenreich PA; Fonarow GC J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]